Japanese
close

FI (list display)

  • A61L33/00
    		•  Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, as well as articles for the manipulation or conditioning of blood; materials for such treatment [4, 7]
    		HB CC 4C081
  • A61L33/00,100
    		•  .Chemical modification of the substrate HB CC 4C081
  • A61L33/00,110
    		•  ..by reacting with an organic compound other than heparin HB CC 4C081
  • A61L33/00,120
    		•  ..by grafting of a monomer onto the substrate HB CC 4C081
  • A61L33/00,200
    		•  ..Physical treatment, e.g. plasma treatment HB CC 4C081
  • A61L33/02
    		•  .Use of inorganic materials [7] HB CC 4C081
  • A61L33/04
    		•  .Use of organic materials, e.g. acetylsalicylic acid [7] HB CC 4C081
  • A61L33/06
    		•  .Use of macromolecular materials [7] HB CC 4C081
  • A61L33/06,100
    		•  ..Mixtures of macromolecular compounds HB CC 4C081
  • A61L33/06,200
    		•  ..obtained by reactions only involving carbon-to-carbon unsaturated bonds HB CC 4C081
  • A61L33/06,210
    		•  ...Rubber HB CC 4C081
  • A61L33/06,300
    		•  ..obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds [7] HB CC 4C081
  • A61L33/08
    		•  ..Polysaccharides [7] HB CC 4C081
  • A61L33/10
    		•  ...Heparin, heparinoid or derivatives thereof [7] HB CC 4C081
  • A61L33/10,100
    		•  ....using an intermediate layer of polymer HB CC 4C081
  • A61L33/12
    		•  ..Polypeptides, proteins or derivatives thereof [7] HB CC 4C081
  • A61L33/14
    		•  .Use of fibrinolytic agents or platelet aggregation inhibitors [7] HB CC 4C081
  • A61L33/14,100
    		•  ..using an intermediate layer of polymer HB CC 4C081
  • A61L33/16
    		•  .Use of enzymes, e.g. urokinase, streptokinase [7] HB CC 4C081
  • A61L33/18
    		•  .Use of ingredients of undetermined constitution or reaction products thereof [7] HB CC 4C081
    TOP